Search Result

Results for "

thrombin-induced aggregation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Protease Activated Receptor (PAR) (4) Thrombin (8) Apoptosis (2) Bacterial (1) Factor Xa (1) Isotope-Labeled Compounds (2) JNK (1) Src (1) Syk (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (13) Infection (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Thrombin Protease Activated Receptor (PAR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162558

NCGC00351170	Factor Xa	Cardiovascular Disease
NCGC00351170 is an antiplatelet agent that disrupts the calcium and integrin-binding protein 1 (CIB1)-α_IIbβ₃ interaction. NCGC00351170 inhibits thrombin-induced human platelet aggregation .

HY-10163

Dabigatran 5 Publications Verification BIBR 953; BIBR 953ZW	Thrombin	Cardiovascular Disease Cancer
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct *thrombin* inhibitor (K_i=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-108419

WHI-P258	JNK	Cancer
WHI-P258, a quinazoline compound, binds to the active site of JAK3 with an estimated K_i of 72 µM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM .

HY-10163S1

Dabigatran-d3 BIBR 953-d₃; BIBR 953ZW-d₃	Thrombin	Cardiovascular Disease
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-117561

DuP 714	Thrombin	Cardiovascular Disease
DuP 714 is an oral active *thrombin* inhibitor with the IC₅₀ values of 150 nM aganist thrombin-induced aggregation in washed human platelets. DuP 714 can be used for study of arterial thrombosi .

HY-N10271

SCH 38519	Bacterial	Infection
SCH 38519 is a platelet aggregation inhibitor. SCH 38519 inhibits thrombin-induced aggregation of human platelets with an IC₅₀ of 68 μg/mL. SCH 38519 is also active against Gram-positive and Gram-negative bacteria .

HY-161867

Platelet aggregation-IN-1	Others	Others
Platelet aggregation-IN-1 (Compound 10e) is an inhibitor for platelet aggregation, that inhibits 100% thrombin-induced platalet aggregation at 50 μM .

HY-108555

FR-171113	Protease Activated Receptor (PAR)	Cardiovascular Disease
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 0.29 μM. .

HY-10163S

Dabigatran-d4 BIBR 953-d₄; BIBR 953ZW-d₄	Isotope-Labeled Compounds Thrombin	Cardiovascular Disease
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-10163R

Dabigatran (Standard)	Thrombin	Cardiovascular Disease Cancer
Dabigatran (Standard) is the analytical standard of Dabigatran. This product is intended for research and analytical applications. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) .

HY-10163S2

Dabigatran-13C6 BIBR 953-¹³C₆; BIBR 953ZW-¹³C₆	Thrombin	Cardiovascular Disease
Dabigatran- ¹³C₆ is the ¹³C labeled Dabigatran[1]. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[2][3].

HY-10163S3

Dabigatran-13C,d3 BIBR 953-¹³C,d₃; BIBR 953ZW-¹³C,d₃	Isotope-Labeled Compounds Thrombin	Cardiovascular Disease
Dabigatran- ¹³C,d₃ is the ¹³C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-19674

SSR182289 SSR182289A free base	Thrombin	Cardiovascular Disease
SSR182289 (SSR182289A free base) is a selective and potent orally active *thrombin* inhibitor. SSR182289 competitively and selectivity inhibits human thrombin (K_i=0.031 μM). SSR182289 demonstrates anticoagulant activity in vitro (thrombin time EC₁₀₀=96 nM) and inhibits tissue factor-induced thrombin generation (IC₅₀=0.15 μM) in human plasma. SSR182289 inhibits thrombin-induced aggregation of human platelets (IC₅₀=32 nM), but has no effect on aggregation induced by other platelet agonists .

HY-78263

MNS NSC 170724; 5-(2-Nitrovinyl)benzodioxole	Src Syk	Cancer
MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC₅₀ values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC₅₀ of 27.3, 2.8, and 97.6 μM, respectively .

HY-14994

SCH79797 dihydrochloride 2 Publications Verification	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .

HY-14993

SCH79797 2 Publications Verification	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .

HY-128345

UDM-001651	Protease Activated Receptor (PAR)	Cardiovascular Disease
UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC₅₀=4 nM; K_d=1.4 nM). UDM-001651 shows antiplatelet potency (IC₅₀=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10271

SCH 38519	Infection Quinones Monophenols Microorganisms Classification of Application Fields Anthraquinones Source classification Phenols Disease Research Fields	Bacterial
SCH 38519 is a platelet aggregation inhibitor. SCH 38519 inhibits thrombin-induced aggregation of human platelets with an IC₅₀ of 68 μg/mL. SCH 38519 is also active against Gram-positive and Gram-negative bacteria .

Cat. No.	Product Name	Chemical Structure

HY-10163S1

Dabigatran-d3
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-10163S

Dabigatran-d4
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

HY-10163S2

Dabigatran-13C6
Dabigatran- ¹³C₆ is the ¹³C labeled Dabigatran[1]. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[2][3].

HY-10163S3

Dabigatran-13C,d3
Dabigatran- ¹³C,d₃ is the ¹³C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

thrombin-induced aggregation

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products